Rotigotine for anxiety during wearing-off in Parkinson's disease with dementia

Aging Clin Exp Res. 2013 Sep 10. [Epub ahead of print]

Fanciulli A, Assogna F, Caltagirone C, Spalletta G, Pontieri FE.

Source

Dipartimento di Neuroscienze, Salute Mentale e Organi di Senso - NeSMOS, "Sapienza" Università di Roma, Via di Grottarossa, 1035, 00189, Rome, Italy.

Abstract

BACKGROUND:

Wearing-off (WO) refers to the exacerbation of motor and/or non-motor symptoms of Parkinson's disease at the end of dose of dopaminergic medications. Treatment of WO is based on modifying drug schedule, meal timetable and/or increasing dopamine replacement therapy. In advanced and/or demented patients, management of WO is often limited by scarce compliance and by cognitive, psychiatric and dysautonomic side-effects that may accompany increased dopaminergic stimulation.

METHODS:

Here, we report 2 patients suffering from Parkinson's disease with dementia, who experienced anxiety as non-motor symptom of WO under stable levodopa therapy. In both cases, transdermal rotigotine (4 mg/day) was added to the original dopaminergic therapy.

RESULTS:

Rotigotine proved beneficial on symptoms of anxiety in both patients, without worsening cognitive and behavioral symptoms. During the 9-month follow-up period, there was a slight improvement of motor impairment, with no worsening of drug-related dyskinesia.

CONCLUSIONS:

These preliminary results suggest that rotigotine at low dose might improve non-motor symptoms of WO in elderly patients suffering from Parkinson's disease with dementia, without raising major safety issues.